Technology | November 29, 2007

Bayer Opens New Door to Contrast Media Safety

Bayer Healthcare Pharmaceuticals responded to concerns by the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) on administering contrast agents by previewing at RSNA 2007 VistaTrak, a password protected contrast media cabinet that tracks media stock using RFID labels.

Designed to help meet JCAHO regulations on safety, the cabinet can be interfaced with an electronic medical record (EMR), PACS/RIS and billing system to access patient data and monitor for allergic reactions. The monitoring system is designed to help prevent the potential risk of nephrogenic systemic fibrosis (NSF) when a patient is injected with gadolinium-containing contrast agents for magnetic resonance imaging (MRI). The company’s MAGNEVIST (gadopentetate dimeglumine) contrast agent will be the first product to carry the RFID tag in the VistaTrak cabinet.

The cabinet is also password protected to comply with JCAHO’s requirement for contrast agent cabinets to be kept under lock and key. The cabinet is only accessible by using either a coded badge or a pin code.

Once a bottle is removed, the RFID tag inside of the cabinet reads the lot number, expiration date and other information on the label required by JCAHO. The EMR, PACS/RIS and billing system are updated when a bottle is removed from the cabinet to track the procedure and inventory. VistaTrak will not be commercially available until mid-2008.

November 2007


Related Content

News | Contrast Media

August 17, 2023 — University of Missouri School of Medicine neurologist Adnan Qureshi, MD recently led a study that ...

Home August 17, 2023
Home
News | Contrast Media

July 3, 2023 — According to an accepted manuscript published in ARRS’ own American Journal of Roentgenology (AJR) ...

Home July 03, 2023
Home
News | Contrast Media

May 11, 2021 — The American Institute of Ultrasound in Medicine (AIUM) and the American Society of Echocardiography (ASE ...

Home May 11, 2021
Home
Technology | Contrast Media

July 15, 2019 — The U.S. Food and Drug Administration (FDA) has approved Gadavist injection for use in cardiac magnetic ...

Home July 15, 2019
Home
Videos | Contrast Media

Sharon Mulvagh, M.D., FASE, FACC, FRCPC, professor of medicine, division of cardiology, Dalhousie University, Halifax ...

Home June 28, 2019
Home
Feature | Contrast Media | Dave Fornell, Editor

Iodine-based contrast agents used in computed tomography (CT) and catheter-based angiography have been implicated as a ...

Home May 31, 2019
Home
News | Contrast Media

May 9, 2019 — Osprey Medical announced the launch of DyeMINISH, a global patient registry to evaluate the ongoing safety ...

Home May 09, 2019
Home
News | Contrast Media

November 30, 2018 — VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that ...

Home November 30, 2018
Home
News | Contrast Media

In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore ...

Home September 12, 2018
Home
News | Contrast Media

January 19, 2018 — Ligand Pharmaceuticals Inc. announced initiation of a program to develop contrast agents with reduced ...

Home January 19, 2018
Home
Subscribe Now